Building a global market access strategy for Asia means selecting priority markets based on commercial potential and regulatory feasibility, then mapping distinct submission pathways for each country. Asia is not a single regulatory bloc — Japan, China, South Korea, and Southeast Asian nations each operate independent frameworks with different data requirements, timelines, and approval logic. The sections below unpack the key questions every biopharmaceutical or medical device company must answer before entering Asian markets.
Which Asian markets should you prioritize first?
The highest-priority Asian markets for most biopharmaceutical and medical device companies are Japan, China, and South Korea, followed by Australia and Singapore as regional hubs. These five markets combine large patient populations or high purchasing power with relatively transparent regulatory systems, making them the most predictable entry points for a structured Asia market access strategy.
Japan offers one of the world’s largest pharmaceutical markets with well-established reimbursement pathways. China’s scale is unmatched, though its approval timelines and local data requirements demand significant planning. South Korea has modernized its regulatory framework substantially and offers faster review timelines for innovative products. Australia, while geographically outside Asia, is frequently included in Asia-Pacific strategies because the Therapeutic Goods Administration operates a well-documented, English-language process. Singapore serves as a strategic base for Southeast Asian expansion through the ASEAN regulatory harmonization initiative.
Prioritization should ultimately be driven by three factors: disease prevalence in the target indication, reimbursement potential, and your organization’s capacity to meet local data requirements. Starting with one or two anchor markets and expanding from there is almost always more effective than attempting simultaneous multi-country submissions. If you would like to understand how our regulatory services can support your market prioritization process, we are happy to walk you through the options.
How do regulatory pathways differ across Asian markets?
Regulatory pathways across Asian markets differ significantly in structure, review timelines, reliance on foreign data, and the degree to which local clinical evidence is required. Unlike the EU or US, there is no pan-Asian regulatory authority, so each country maintains its own submission format, dossier requirements, and approval logic.
Japan: PMDA’s consultative model
The Pharmaceuticals and Medical Devices Agency (PMDA) in Japan operates a consultative review model that encourages pre-submission meetings. PMDA in Japan is known for its rigorous scientific standards and has historically required bridging studies to confirm that foreign clinical data apply to Japanese patients. Under the Sakigake designation, priority review is available for innovative products addressing unmet medical needs, which can reduce timelines substantially.
China: NMPA’s evolving framework
China’s National Medical Products Administration has undergone significant reform since joining the International Council for Harmonisation (ICH). The NMPA now accepts more foreign clinical data than it did a decade ago, but local clinical trial requirements or verification studies remain common for many product categories. Marketing authorization timelines vary widely depending on product classification and whether priority review applies.
South Korea and Southeast Asia
South Korea’s Ministry of Food and Drug Safety (MFDS) follows a pathway broadly aligned with ICH guidelines and accepts foreign clinical data with appropriate bridging justification. Southeast Asian markets such as Thailand, Indonesia, Malaysia, and the Philippines each maintain national agencies, though the ASEAN Common Technical Dossier format provides some harmonization for submissions across the region.
What data requirements are unique to Asian regulators?
The most distinctive data requirement across Asian regulatory submissions is the expectation of ethnic sensitivity data, often in the form of bridging studies or pharmacokinetic comparisons in Asian patient populations. Many Asian regulators want evidence that efficacy and safety profiles established in predominantly Western clinical trials translate to their populations before granting approval.
Japan’s PMDA has historically been the most explicit about this, requiring bridging studies under ICH E5 guidelines when pivotal trials did not include sufficient Japanese subjects. China’s NMPA has similar expectations, and while reforms have relaxed the requirement for full local trials in some cases, sponsors must still justify the applicability of foreign data. South Korea and Taiwan apply analogous principles.
Beyond ethnic sensitivity, Asian regulators often require locally manufactured or locally tested reference standards, country-specific labeling in the national language, and post-approval commitments such as pharmacovigilance plans tailored to local reporting systems. Some markets also require local authorized representatives or in-country agents as a condition of registration, which has operational and legal implications companies should address early in their Asia regulatory strategy. Learning more about our team and background can help you assess whether our expertise aligns with the specific markets you are targeting.
How does China’s NMPA approval process work?
China’s NMPA approval process for drugs follows a structured pathway that begins with an Investigational New Drug (IND) application or a direct New Drug Application (NDA) if the product is already approved in a reference jurisdiction. Since 2017, China has accepted applications for products without prior domestic clinical trials in certain categories, a significant shift from the previous mandatory local trial requirement.
The process broadly involves the following stages:
- Pre-submission preparation: Assembling the Common Technical Document (CTD) dossier aligned with NMPA formatting requirements, including Chinese-language summaries.
- Formal submission and acceptance review: NMPA screens the application for completeness before accepting it for substantive review.
- Technical review: Reviewers assess quality, safety, and efficacy data. Supplementary questions are common, and response timelines affect the overall clock.
- On-site inspection: GMP inspections of manufacturing facilities, including foreign sites, are typically required before approval.
- Approval and registration: Upon successful review and inspection, the marketing authorization is issued.
Priority review designations are available for breakthrough therapies, rare diseases, and products addressing urgent public health needs. Companies pursuing NMPA China approval should plan for the possibility of a local verification or bridging study, particularly for biologics, and should factor GMP inspection scheduling into their overall timeline.
What are the biggest regulatory risks when entering Asian markets?
The biggest regulatory risks when entering Asian markets are underestimating local data requirements, failing to plan for GMP inspections of foreign manufacturing sites, and misreading the pace of regulatory reform. Each of these can cause significant delays or outright rejection of submissions.
Underestimating local data requirements is the most common pitfall. Companies that assume their FDA or EMA approval package will transfer directly to Asian submissions often face requests for bridging studies, additional stability data under regional climatic conditions, or locally validated analytical methods. Building these requirements into development planning from the start avoids costly late-stage gaps.
GMP inspections represent a separate but equally significant risk. Both NMPA China and PMDA Japan conduct inspections of foreign manufacturing facilities as part of the approval process. Scheduling delays, inspection findings, or facility changes during the review period can extend timelines by months or longer. Maintaining manufacturing sites in a constant state of inspection readiness is essential for companies with active Asian registration strategies.
Regulatory reform adds a layer of strategic uncertainty. Asian regulatory agencies are evolving rapidly, and guidance documents, fee structures, and data requirements can change between the time a strategy is designed and the time a submission is filed. Monitoring regulatory intelligence from agencies like PMDA Japan and NMPA China on an ongoing basis is a necessary part of any Asia market entry strategy.
When should you involve a regulatory consultant for Asia market access?
You should involve a regulatory consultant for Asia market access as early as the product development stage, ideally before clinical trial design is finalized. Decisions made in Phase II or Phase III about patient population composition, comparators, and endpoints can determine whether your data package will satisfy Asian regulators years later.
Consultants add the most value at three specific moments. First, during regulatory pathway mapping, when a company needs to determine which markets to pursue, in what order, and through which submission routes. Second, during dossier preparation, where knowledge of country-specific formatting, language requirements, and technical expectations prevents avoidable deficiencies. Third, during the response phase, when regulators issue questions and a well-calibrated scientific response can determine whether a review cycle closes in months or extends by a year.
Companies without in-house Asian regulatory expertise should also consider involving a consultant when planning GMP inspections, negotiating post-approval commitments, or evaluating whether a product qualifies for accelerated or priority review designations in markets like Japan or China. Get in touch with us to discuss where in your development timeline it makes the most sense to bring in dedicated regulatory support.
How Starodub supports your Asia market access strategy
We work with biopharmaceutical and medical device companies at every stage of their Asia regulatory strategy, from initial market selection through submission preparation and post-approval maintenance. Our team combines hands-on regulatory CMC expertise with a broad network of country-specific specialists, giving you both scientific depth and local knowledge without the overhead of building that capability in-house.
Specifically, we can support your Asia market entry strategy by:
- Mapping regulatory pathways across Japan (PMDA), China (NMPA), South Korea (MFDS), and Southeast Asian markets
- Identifying bridging study requirements and ethnic sensitivity data gaps early in development
- Preparing and reviewing CTD dossiers formatted for country-specific submission requirements
- Supporting GMP inspection readiness for foreign manufacturing sites
- Drafting responses to regulatory questions and managing review cycles
- Providing ongoing regulatory intelligence monitoring as Asian frameworks evolve
Whether you are entering Asian markets for the first time or expanding an existing registration portfolio, we provide the regulatory expertise to move efficiently and avoid costly missteps. Contact Starodub to discuss your Asia market access strategy and find out how we can support your path to approval.
